TW426685B - Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac - Google Patents

Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac Download PDF

Info

Publication number
TW426685B
TW426685B TW86110781A TW86110781A TW426685B TW 426685 B TW426685 B TW 426685B TW 86110781 A TW86110781 A TW 86110781A TW 86110781 A TW86110781 A TW 86110781A TW 426685 B TW426685 B TW 426685B
Authority
TW
Taiwan
Prior art keywords
scope
item
ester
patent application
crystallization
Prior art date
Application number
TW86110781A
Other languages
Chinese (zh)
Inventor
Shian-Yan Tzou
Jin-Lu Tzeng
Sz-Feng Chen
Original Assignee
Dev Center Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Center Biotechnology filed Critical Dev Center Biotechnology
Priority to TW86110781A priority Critical patent/TW426685B/en
Application granted granted Critical
Publication of TW426685B publication Critical patent/TW426685B/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention pertains to a method for the optical resolution of (±)-etodolac-an antiarthritic drug, comprising the following steps: (1) the formation of diastereoisomeric esters between (±)-etodolac and (1R, 2R, 3R, 5S)-(-)-isopinocamphenol, comprising the direct cyclization of 7-ethyltryptophol with a 3-ketopentanoic ester or its enol ether derivative to form said diastereoisomeric esters, wherein the 3-ketopentanoic ester was prepared by the esterification of 3-ketopentanoic acid with (1R, 2R, 3R, 5S)-(-)-isopinocamphenol; (2) the fractional crystallization and isolation of the resultant diastereoisomeric esters in an appropriate solvent; and (3) the recovery of etodolac with high optical purity and (1R, 2R, 3R, 5S)-isopinocamphenol. The present invention also pertains to the diastereomeric esters of etodolac.

Description

經濟部中央標隼局員工消費合作社印策 42β68 5 . Α7 -----Β7_ 五、發明説明(1 ) 發明背景 伊托多适疋由美國Wyeth-Ayerst Laboratories所開發之 一種非固醇類消炎劑,其商品名稱爲L〇dine,在臨床上係 用來治療關節炎。由於世界各國老年人口有增加的趨勢, 因此其使用量亦可能随之增加。 伊托;? S之化學結構具有—個含幾酸取代基之不對稱中 心’因此適合藉由光學解析法以單離各別光學異構物。 關於(±)_伊托多雷,(+)_伊粍多雷與伊托多雷所具有 之抗發炎活性比較’已由Demerson, C. A‘等人發表,其所 公佈之一項體外藥理試驗結果顯示,上述各化合物對花生 四烯酸之抑制活性如下:(土)_伊托多雷:IC5〇 = 24〇 μ1νΙ,( + > 伊托多雷:IC50=12O μΜ ’㈠-伊托多雷:ic50>4OO μΜ (見Instruction of the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 42β68 5. Α7 ----- Β7_ V. Description of the invention (1) Background of the invention Itodoxamine is a non-steroidal anti-inflammatory developed by Wyeth-Ayerst Laboratories in the United States Agent, whose trade name is Lodine, is used clinically to treat arthritis. Due to the increasing trend of the elderly population in various countries around the world, its use may also increase accordingly. The chemical structure of ITO; S has an asymmetric center containing several acid substituents, and is therefore suitable for the separation of individual optical isomers by optical analysis. About (±) _Itodore, (+) _ Comparison of anti-inflammatory activity between Itodol and Itodore 'has been published by Demerson, C. A, et al. The results of pharmacological tests show that the inhibitory activities of the above compounds on arachidonic acid are as follows: (soil) _Itodolite: IC50 = 24〇μ1νΙ, (+ > Itodolite: IC50 = 12O μΜ '㈠- Itodore: ic50 > 4OO μΜ (see

Demerson, C. A., Humbers L. G,, Abraham, N. A., Schilling, G.5 Martel, R. R., Pace-Asciak, C. J. Med. Chem., 1983 26 > ,, 1778)。由此判斷,伊托多雷在本質上較(±)_伊托多雷 及(-)-伊托多雷具有較佳之抗發炎活性,其對人體的藥效 亦可能較佳’且副作用亦可能較低。以上判斷已得到一部 分證實。英國CHIROSCIENCE公司之一國際專利(專利公開 案號W0 95/27713)揭示一種由L-還原葡糖胺或其烷化衍生 物與伊耗多雷所生成之鹽,其可逕行用之於人體,因爲, L-還原葡糖胺是一種可爲人體所接受之胺醣衍生物。其所 公佈的一項人體試驗結果顯示,( + 伊托多雷與^還原葡糖 胺衍生物所形成之鹽具有較佳之消炎及止痛功效。其中(+)-伊托多雷係以L-還原葡糖胺爲光學解析試劑,藉由(±)_伊托 ---- -—... - ------ - _- 4 -_ 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公慶) (請先閱讀背面之注意事項再填寫本頁)Demerson, C. A., Humbers L. G ,, Abraham, N. A., Schilling, G. 5 Martel, R. R., Pace-Asciak, C. J. Med. Chem., 1983 26 > ,, 1778). Judging from this, itodore has substantially better anti-inflammatory activity than (±) _Itodore and (-)-Itodore, and its effect on the human body may also be better. May be lower. The above judgment has been partially confirmed. An international patent (patent publication number WO 95/27713) of the British CHIROSCIENCE company discloses a salt formed by L-reduced glucosamine or its alkylated derivative and isodore, which can be applied to the human body. Because, L-reducing glucosamine is an amine sugar derivative acceptable to the human body. The results of a human test published by it show that the salt formed by (+ Itodolite and ^ reduced glucosamine derivatives has better anti-inflammatory and analgesic effects. Among them, (+)-Itodolite is based on L- Reduced glucosamine is an optical analysis reagent, with (±) _Ito ------...--------_- 4 -_ This paper size applies to the Chinese National Standard (CNS) Λ4 Specifications (210X297 public holidays) (Please read the precautions on the back before filling in this page)

*1T 426685. Α7 Β7 五、發明说明(2) … 多雷之光學解析作用所製備。 有關伊托多雷光學解析之先前技藝,亦僅由以上二篇文 獻所揭示。其中Demerson等人曾將(±)-伊托多雷與樟腦醇 (L-(-)-b〇rne〇l)進行酯化反應,以製備非對映體異構物,然 後利用掌性管柱(chiraicolumn)進行大量分離(50克規模), 最後再進行水解以得到各別之伊托多雷單一光學異構物。 由於層析法需採用大量且昂貴之固相,又需使用大量的溶 劑’其雖可製備出足量之單一光學異構物供藥理試驗用, 但就經濟效益而言,並不具有產業上可利用價値。而利用 L-還原葡糖胺及其烷化衍生物作爲光學解析試劑,雖可成 功地分離出伊托多雷單一光學異構物’然而,無論是卜還 原葡糖胺或其烷化衍生物均具有高度的水溶性,其雖可達 成伊托多雷之光學解析目的,但由於無法回收,因此其用 途僅侷限於伊托多雷-L-還原葡糖胺鹽衍生物本身之應用。 發明簡要説明 本發明係關伊托多雷之分學解析方法,其包括1 )形成(土)· 伊托多雷與(1R,2R,3R,5SH-)異松藻醇之酸類非對映體 異構物’ .2)那份結晶及單離所形成之酯類非對映體異構物 ’及3)回收高光學純度之伊托多雷及(1R,2R,3R,5SH_)_ 異松藻醇。根據本發明之方法,(1R,2R,3R,5S)•㈠_異松 藻醇之回收率可達97%以上β本發明另—方面係關上述伊 托多雷與異松藻醇之新穎酯類非對映體異構物。 發明詳述. " 本發明係關伊托多雷之光學解析方法,其包括下述步驟 ____ -5- 本紙張尺度適用中國國家標隼(CNS > Α4現格(210Χ2的公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央榡準局員工消费合作社印製 426685, A7 B7 五、發明説明(3 ) :1)形成(±)-伊托多雷與(1R,2R,3R,55)_(_)1異松藻醇之 酯類非對映體異構物,包括將(±)_伊托多雷直接與(1R,2R, 3R,5SH-)異松藻醇直接反應生成孩雙類非對映體異構物丨 ,或將7_乙基色醇與—種3二酿]基_戊酸酯或其烯醚衍生物經 環化反應以生成該醋類非對映體異構物,其中該3_酮基戊 酸酯係由3-酮基戊酸與(1R,2R,3R,5S)_(—)_異松藻醇之酯 化反應所製得者;2)將所生成之酯類非對映體異構物在適 當溶劑中進行部份結晶與單離;及乃回收高光學純度之伊 托多雷與(1R,2R,3R,5S)-㈠-異松藻醇。 一 本發明方法所涉及之反應流程如下: a) 洱 (請先閱讀背面之注意事項再填寫本頁)* 1T 426685. Α7 Β7 V. Description of the invention (2)… prepared by the optical analysis of Dore. The previous techniques of itotore's optical analysis are also revealed only by the above two articles. Among them, Demerson et al. Used (±) -Itodoleide and camphor alcohol (L-(-)-borneol) to make an esterification reaction to prepare diastereomers, and then used the palmar tube The column (chiraicolumn) was subjected to a large number of separations (50 g scale), and finally subjected to hydrolysis to obtain the individual itodore single optical isomers. Because chromatography requires a large number of expensive solid phases and a large number of solvents', although it can prepare a sufficient amount of a single optical isomer for pharmacological testing, it is not industrially effective in terms of economic benefits. Available price. Using L-reduced glucosamine and its alkylated derivatives as optical analytical reagents, it is possible to successfully isolate a single optical isomer of itodole '. However, whether it is reduced glucosamine or its alkylated derivatives Both are highly water-soluble. Although it can achieve the purpose of optical analysis of Itodore, it cannot be recycled, so its use is limited to the application of Itodore-L-reducing glucosamine salt derivative itself. Brief description of the invention The invention is a method for analyzing the micro-analysis of Guantodore, which includes 1) the formation of (soil) · Itodole and (1R, 2R, 3R, 5SH-) isoanthopic acid diastereomers Isomers '. 2) The diastereoisomers of esters formed by the crystals and the separations' and 3) Recovering itodolite and (1R, 2R, 3R, 5SH _) _ with high optical purity Isoprenol. According to the method of the present invention, the recovery rate of (1R, 2R, 3R, 5S) • ㈠_isoospolenol can reach more than 97% β. Another aspect of the present invention relates to the novelity of the above-mentioned itodorol and isosporol. Ester diastereomers. Detailed description of the invention. &Quot; The present invention is an optical analysis method of Guan Yi Todorei, which includes the following steps ____ -5- This paper size is applicable to the Chinese national standard (CNS > A4 present grid (210 × 2 mm) (Please read the precautions on the back before filling out this page) Order printed by the Consumers Cooperative of the Central Economic and Technical Bureau of the Ministry of Economic Affairs 426685, A7 B7 V. Invention Description (3): 1) Formation (±)-Itodore and ( 1R, 2R, 3R, 55) _ (_) 1 Esterisomeric isomers, including (±) _Itodol and (1R, 2R, 3R, 5SH-) Isoprenol is directly reacted to form diastereoisomers, or 7-ethyl tryptanol is reacted with a kind of 3 bis-] valerate or its ether derivative through cyclization reaction to produce The acetic diastereoisomer, wherein the 3-ketovalerate is esterified with 3-ketovaleric acid and (1R, 2R, 3R, 5S) _ (-) _ isosinol Those obtained by the reaction; 2) Partial crystallization and single ionization of the ester diastereomers formed in an appropriate solvent; and recovery of Itodol and (1R, 2R, 3R, 5S) -fluorene-isosperbutanol. The reaction process involved in the method of the present invention is as follows: a) 洱 (Please read the precautions on the back before filling this page)

D. C, C.(或E. D. C,) cha (1R; 2R, 3R, 5S)-(.). 異松藻醇 訂 經濟部中央標準局員工消费合作社印製 CH,D. C, C. (or E. D. C,) cha (1R; 2R, 3R, 5S)-(.). Isoporoxol Order CH Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs,

1)部份結晶1) Partial crystallization

c2H5 或 2) '0H7CH,0H, Up 3) H30 +c2H5 or 2) '0H7CH, 0H, Up 3) H30 +

\/〇2h\ / 〇2h

0.H 本紙張尺度適用中國國家標準(CNS〉Λ4規格(210 x 297公慶) ^2668 5 . A7 五、發明説明(4) b)0.H This paper size applies the Chinese national standard (CNS> Λ4 specification (210 x 297 public holidays) ^ 2668 5. A7 V. Description of the invention (4) b)

Ο Ο 00 HO + 、OHΟ Ο 00 HO +, OH

Ο οΟ ο

ΟΗ〇Η

或 路易士酸 (請先閲讀背面之注意事項再填寫本頁) CA 7-乙基色醇Or Lewis acid (please read the notes on the back before filling this page) CA 7-ethyl tryptanol

-a 經濟部中央樣準局貝工消費合作社印裂-a Printed by the Shell Sample Consumer Cooperative of the Central Bureau of Procurement, Ministry of Economic Affairs

t- 1)部份結晶 2) -OH/O^OR H^O 3) I^O +t- 1) partly crystalline 2) -OH / O ^ OR H ^ O 3) I ^ O +

本紙張尺度適用中國國家標準(CNS ) Λ4規格(2丨0乂297公釐} 經濟部中央標準局員工消費合作社印裝 42668 5, a7 A7 __ B7 五、發明説明(5 ) " 根據本發明方法之第一步驟,如上述反應流程所示,伊 乾多雷非對映體異構物可經由二種不同之途徑製備: 1) (±)-伊托多雷與(1R,2R,3R, 5SH_)_異松藻醇於適當溶 劑中,在脱水劑例如D.C.C或E.D.C存在下直接生成^度 結晶性酯類非對映體異構物,其中(1R,2R,3R,58)_卜> 異松藻醇可商業購得,或可由廉價之蒎烯經氫领化作用 ,甲氧化作用與氧化作用三個連續步驟製得,此一製備 方法可參考 Organic Syntheses,Coll. Vol. VI. 719。 2) 7-乙基色醇與一種3_酮基戊酸酯或其烯醚衍生物進行環 化反應以生成上述酯類非對映體異構物,其中該3_酮基 戊酸酯係由3-酮基戊酸與(1R,2R,3R,5S)-卜)-異松藥酵 之酯化反應而製得。7-乙基色醇之製備係技藝中所已知 者’例如可參考美國專利第3,843,681號(1974)。 本發明上述第二種途徑所涉及之環化反應,需經酸催化 ,而經由一系列酸之測試結果顯示,其中以路易士酸較佳 ,例如BF^OEh或BF3。此外,環化反應物中,3_酮基戊酸 酯之烯醚衍生物之活性較3-酮基戊酸酯之活性爲佳。當環 化反應物具有較高活性時,不僅可減少路易士酸之用量, 且可提高環化反應之產率。 上述由(-)-異松藻醇所衍生之3-酮基戊酸酯之製備方式 如下:1) 3-酮基戊酸與(1R,2R,3R,5S)-(-)-異松藻醇在脱 水劑(例如D.C.C或E.D.C)存在下生导酯類非對映體異構物 ;2)將所得醋類竹生物與三甲基原甲酸醋(trimethyloiftho-formate),在酸性催化劑存在下,生成晞醚型衍生物,其中 -8- 本紙張尺度適用中國國家標準(CNS ) Λ4規格(2IOXN7公犛) ----------)------,1τ------^「 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局—工消費合作社印製 /12R68 5 . A7 ______B7 五、發明説明(6 ) 酸催化劑可爲對甲苯磺酸或DOWEX-50W酸性樹脂。 吾等已針對本發明光學解析方法之各條件進行深入研究 及測試,測試結果發現:1)本發明方法所使用之較佳溶劑 鳥醇類,其中以無水乙醇較佳,2)(土)-伊托多雷與(1R, 2R, 3R,5 S)異松藻醇所生成之酯類在無水乙醇中之較佳濃 度爲0‘135克/晕升至〇 145克/毫升,其中以〇 140克/毫升較 佳’亦即在此濃度範園下,可獲較佳之回收率與光學純度 ’ 3)晶種之添加可加速結晶之形成且能提高產物之光學純 度’其中晶種係由經光學離析之各別單—光學異構物(+)_ 伊托多雷或(-)-伊托多雷與(1R,2R,3R,5S)-(-)-異松藻醇 在脱水劑D.C‘C或E.D.C存在下生成各別之酯類化合物所製 備而得,4)部份結晶之操作溫度可以在室溫或低於室溫下 進行’而在低於室溫之情況下可藉晶種之加入而縮短結晶 期及提高產物之光學純度。 本發明方法將進一步以下述實例作一説明,唯其非欲用 以限定本發明之範圍。 實例1 (±)-伊托多雷與(1R, 2R, 3R,5S)-(-)-異松蔆醇之验厶作甲 以製備酯類非對映體異構物 取(±)_伊托多雷(20克,0.07莫耳)’ 4-(二甲基胺)吡啶(1 〇 克)與(1R,2R,3R,5S)-(-)-異松藻醇(12.9 克,〇_〇84 莫耳)依 次加入6 0 0毫升無水乙酸中,冰浴至〇 C ’接著加入d . c. c (18‘2克,0.0 88莫耳),然後於室溫下攪拌12小時。將所得 溶液過濾,所得濾液經濃縮後,將所得殘留物經由一小段 ________ - 9 -________ 本紙張尺度適用中國國家標準(CNS } Λ4規格(210Χ24^¥] ' " .(請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央栳準局員工消費合作社印製 42668 5 . A7 ___B7____ 五、發明説明(7 ) 矽膠管柱層析,並以正已烷-乙酸乙酯(10: 1體積比)爲沖提 液,得到所欲之非對映異構物(30.2克,97.6%)。熔點爲 115-117〇C 0 NMR (CDC13, 500 MHz) 9.17 (brs, 1H), 7.35 (d, J=7.0 Hz, 1H), 7.05 (m, 1H), 7.00 (d, J-6.70 Hz, 1H), 5.10 (m,1H),4.03 (m,1H),3.95 (m,1H), 2.80-3.00 (m,4H), 1.50-2.80 (m, ,5H), 1.37 (t, J=7.0 Hz, 3H), 1.22 (s, 3H), 1.12 (d, J=7.50 Hz, 1H), 1.05 (d, J=7.5 Hz, 1H), 0.98 (s, 3H), 0.87 (t, J=7.0 Hz, 3H)» MS(EI) : m/z(相對強度)423(M + , 35), 394(28),25 8(42),228(100)。如以E.D.C取代 D.C.C重複上 i 述相同之縮合反應,則只要經過水洗與濃縮二個步驟即可 得到所欲之非對映體異構物。 實例2 3-酮基戊酸酯之製備 重覆實例1所述步驟,唯以3-酮基戊酸(8.12克,0.07莫耳 )取代(±)-伊托多雷以得到所欲化合物(15.88克,90%)。所 得化合物爲一黃色油狀物,WNMR^CDCh,200 MHz) 5.11 (m, 1H), 3.45 (s, 2H), 3.18 (m, 1H), 2.59 (m, 1H), 2.58 (q, J = 7.2 Hz, 2H), 0.90-2.50 (m, 17H) » 實例3 3-酮基戊酸酯之烯醚衍生物之製備 取3-酮基戊酸酯(6.16克,24.44毫莫耳)溶於200毫升三甲 基原甲酸酯中,加入10克DOWEX-^OW酸性樹脂,迴流加 熱10小時後,所得溶液經過濾後進行減壓濃縮及眞空蒸餾 以去除過剩之三甲基原甲酸酯,得到3 -酮基戊酸酯之烯醚 ______-1Q-______ 本紙張尺度適用中國國家標準(CNS ) Λ4规格(公釐) {請先閲讀背面之注意事項再填寫本頁}This paper size applies to the Chinese National Standard (CNS) Λ4 specification (2 丨 0 公 297 mm) printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 42668 5, a7 A7 __ B7 V. Description of the invention (5) " According to the invention In the first step of the method, as shown in the above reaction scheme, the diastereomers of Igandoretide can be prepared in two different ways: 1) (±) -Itodole and (1R, 2R, 3R , 5SH _) _ Isosinol in a suitable solvent, directly in the presence of a dehydrating agent such as DCC or EDC to form ^ degree crystalline ester diastereomers, of which (1R, 2R, 3R, 58) _bu > Isospinol is commercially available, or it can be prepared from the inexpensive pinene through hydrogenation, methylation and oxidation in three consecutive steps. For the preparation method, refer to Organic Syntheses, Coll. Vol. VI. . 719. 2) 7-ethylchromeol is cyclized with a 3-ketovalerate or its ene ether derivative to generate the above-mentioned ester diastereomers, wherein the 3-ketovalerate is composed of 3-ketovaleric acid is prepared by esterification with (1R, 2R, 3R, 5S) -b) -isopinepine. 7-ethyltryptanol is known in the art, for example, U.S. Patent No. 3,843,681 (1974). The cyclization reaction involved in the second pathway of the present invention needs to be catalyzed by an acid, and a series of acid test results show that a Lewis acid is preferred, such as BF ^ OEh or BF3. In addition, in the cyclization reaction, the activity of the allyl ether derivative of 3-ketovalerate is better than that of 3-ketovalerate. When the cyclization reactant has high activity, not only the amount of Lewis acid can be reduced, but also the yield of the cyclization reaction can be improved. The above-mentioned 3-ketovalerate derived from (-)-isospercatenol is prepared as follows: 1) 3-ketovaleric acid and (1R, 2R, 3R, 5S)-(-)-iso pine Alcohol generates ester diastereomers in the presence of a dehydrating agent (such as DCC or EDC); 2) the obtained vinegar bamboo organism and trimethyloiftho-formate in the presence of an acid catalyst In the following, fluorenyl ether derivatives are formed, of which -8- This paper size is applicable to the Chinese National Standard (CNS) Λ4 specification (2IOXN7 male 牦) ----------) ------, 1τ- ----- ^ 「(Please read the notes on the back before filling out this page) Printed by the Central Bureau of Standards of the Ministry of Economic Affairs—Industrial and Consumer Cooperatives / 12R68 5. A7 ______B7 V. Description of the invention (6) The acid catalyst can be p-toluene Sulfuric acid or DOWEX-50W acid resin. We have carried out in-depth research and testing on the conditions of the optical analysis method of the present invention, and the test results have found that: 1) the preferred solvent used in the method of the present invention is ornithanol, among which absolute ethanol Preferably, the preferred concentration of the esters produced by 2) (soil) -Itodole and (1R, 2R, 3R, 5 S) isosinate in absolute ethanol is 0'135 / Halo rose to 0145 g / ml, of which 0140 g / ml is better, that is, at this concentration range, better recovery rate and optical purity can be obtained. 3) The addition of seed crystals can accelerate the formation of crystals. And can improve the optical purity of the product 'wherein the seed system is separated from the optically separated individual-optical isomers (+) _ Itodore or (-)-Itodore and (1R, 2R, 3R, 5S)-(-)-Isoporoxol is prepared by generating separate ester compounds in the presence of dehydrating agent DC'C or EDC. 4) The operating temperature of partial crystallization can be at or below room temperature. Under the condition of below room temperature, the crystallization period can be shortened and the optical purity of the product can be improved by the addition of seed crystals. The method of the present invention will be further illustrated by the following examples, but it is not intended to limit the present invention. Example 1 The test of (±) -Itodole and (1R, 2R, 3R, 5S)-(-)-isospinolinol was used as a formature to prepare ester diastereomers. ( ±) _Itodol (20 g, 0.07 mole) '4- (dimethylamine) pyridine (10 g) and (1R, 2R, 3R, 5S)-(-)-isosperbutanol ( 12.9 g, 〇_〇84 Mol) was sequentially added to 600 ml of anhydrous acetic acid, and the solution was ice-cooled to 0 ° C, followed by d.c.c (18'2 g, 0.088 mole), and then stirred at room temperature for 12 hours. The resulting solution was After filtration, the obtained filtrate was concentrated, and the obtained residue was passed through a short section of ________-9 -________ This paper size is applicable to the Chinese national standard (CNS) Λ4 specification (210 × 24 ^ ¥) '". (Please read the precautions on the back first Fill out this page again) Order 42668 printed by the Employees' Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs 5. A7 ___B7____ V. Description of the invention (7) Silica gel column chromatography, and n-hexane-ethyl acetate (10: 1 volume ratio ) As the eluent to obtain the desired diastereomer (30.2 g, 97.6%). 115-117 ° C 0 NMR (CDC13, 500 MHz) 9.17 (brs, 1H), 7.35 (d, J = 7.0 Hz, 1H), 7.05 (m, 1H), 7.00 (d, J-6.70 Hz, 1H), 5.10 (m, 1H), 4.03 (m, 1H), 3.95 (m, 1H), 2.80-3.00 (m, 4H), 1.50-2.80 (m,, 5H), 1.37 (t, J = 7.0 Hz, 3H), 1.22 (s, 3H), 1.12 (d, J = 7.50 Hz, 1H), 1.05 (d, J = 7.5 Hz, 1H), 0.98 (s, 3H), 0.87 (t, J = 7.0 Hz, 3H) »MS (EI): m / z (relative intensity) 423 (M +, 35), 394 (28), 25 8 (42), 228 (100). If E.D.C is used instead of D.C.C to repeat the same condensation reaction as described above, the desired diastereomers can be obtained by simply washing and concentrating the water. Example 2 Preparation of 3-ketovalerate The procedure described in Example 1 was repeated, except that (±) -itodole was replaced with 3-ketovaleric acid (8.12 g, 0.07 mole) to obtain the desired compound ( 15.88 g, 90%). The obtained compound was a yellow oil, WNMR ^ CDCh, 200 MHz) 5.11 (m, 1H), 3.45 (s, 2H), 3.18 (m, 1H), 2.59 (m, 1H), 2.58 (q, J = 7.2 Hz, 2H), 0.90-2.50 (m, 17H) »Example 3 Preparation of an allyl ether derivative of 3-ketovalerate Dissolve 3-ketovalerate (6.16 g, 24.44 mmol) in In 200 ml of trimethyl orthoformate, 10 g of DOWEX- ^ OW acid resin was added, and after heating under reflux for 10 hours, the resulting solution was filtered and concentrated under reduced pressure and vacuum distillation to remove excess trimethyl orthoformate. To obtain the 3-ether ketovalerate ether ______- 1Q -______ This paper size is applicable to the Chinese National Standard (CNS) Λ4 specification (mm) {Please read the precautions on the back before filling this page}

經濟部中央標準局—工消費合作社印製 /12 6 6 8 5 , A7 B7 五、發明説明(8 ) 衍生物(5.7克,87.66%)。其爲一白色固體,熔點爲48。-49 °C > *H NMR (CDC13, 500 MHz), 5.11 (m, 1H), 4.99 (s, 1H), 3.65 (s, 3H), 2.79 (m, 2H), 2.60 (m, 1H), 2.40 (m, 1H), 2.15 (m, 1H), 1.95 (m, 1H), 1.85 (m, 1H), 1.73 (m, 2H), 1.24 (s, 3H),1.11 (m,6H),0.97 (s, 3H) 〇 若以對曱苯.磺酸(1克)取代DOWEX-50W進行相同反應, 經眞空蒸餾除去過剩之三甲基原甲酸酯後,將濃縮液以二 氣甲烷稀釋,再生後以10% NaC〇3溶液清洗再以水清洗, 有機液以無水硫酸鎂乾燥後,濃縮獲得3-酮基戊酸酯之缔-醚衍生物(5.16克,80%)。 實例4 7-乙基色醇與.3-酮基戊酸酯之環化作用以製備酯類非讲映 體異構物 將7-乙基色醇(22.5克,0.119莫耳)與由實例2所製得之3-酮基戊酸酯(30克,0.119莫耳)溶於乾燥二氣甲烷(5 00毫升) 中,加入;8?3(^12(1〇毫升,〇.〇796莫耳),然後在室溫下攪 拌12小時,所得溶液經冰水稀釋後,再以1 〇%碳酸鈉水溶 液清洗,再以水清洗,有機溶液經無水硫酸_鎂乾燥後進行 濃縮,殘留物以苯與石油醚之混合溶劑作再結晶以獲得所 欲之非對映體異構物(3 1克,60%) 〇其分析數據與由實例1 所製得之化合物相同,經HtLC分析(掌性管柱),二異構物 之比例約爲1 : 1。 實例5 7-乙基色醇與3 -酮基戊酸酯之烯醚衍生物之環化作用以製 本紙張尺度適用中國國家標準(CNS ) A4规格(210 X 297公釐) --------「—! ^------訂------r「 f請先閲靖背面之注意事項再填寫本頁) 4 2668 5 . 經濟部中央橾準局員工消費合作社印製 A7 B7 五、發明説明(9 ) 備酯類非對映體異構物 將7-乙基色醇(29.2克’ 0.154莫耳)與由實例3所製得之3_ 酮基戊酸酯之婦醚衍生物(4.1克,0,154莫耳)溶於乾燥二氣 甲烷(2500毫升)中’加入催化量之BF3OEt2(0.6毫升,4.77 毫莫耳)’然後在室溫下攪拌2小時,所得之溶液經冰水稀 釋後’再以1Q%碳酸氫鈉水溶液清洗,然後再以水清洗。 有機溶液經無水硫酸鎂乾燥後進行濃縮,殘留物以苯與石 油醚之混合溶劑作再結晶以得到所欲之非對映體異構物 (58克’ 89%)。其分析數據與由實例1所製得之化合物相同 ’經HPLC分析(掌性管.柱),二異構物之比例約爲1 : 1。 實例6 酯類非對映體異構物之部份結晶作用 將由實例4或5所製得之酯類非對映體異構物(1〇克, 0.0236莫耳)加入70毫升無水乙醇中,經過ι〇_15分鐘攪拌後 ’溶液呈現澄清狀。接著’當溶液冷卻至室溫後,加入5〇 毫克由(+)-伊托多雷與(1R,2R, 3R,5SH-)-異松藻醇經酯 化所形成之酯類化合物作爲晶種,然後於〇°C下靜置4小時 β過滤收集所得之針狀結晶物(5.99克,60%),溶點爲 115-117°C,[a]D=-72。(c=l‘0,乙醇)。 實例7 (十伊托多雷與(1R,2R, 3R,5SV1松藻醇之回此 取由實例6所早離出之針狀結晶克,莫耳) 與氫氧化鉀(3.5克,0.06 25莫耳)加入甲醇(1〇〇毫升)與水(26 毫升)中’然後迴流加熱2小時,所得溶液經減壓蒸餾除去 本纸張尺度適用中國國家標準(CNS ) Λ4規樁(210X^7公後)" ---------V------訂-------,「 (請先閲讀背面之注意事項再填寫本頁} A7 五、發明説明(10 ) 甲醇,殘留液以水稀釋後,#以二氣甲烷萃取,萃取液經 乾燥與濃縮回收得到(1R,2R,3R,5S)_異松藻崞(2 38克, 98 /〇),其所有分析數據皆與市售標準品相同。水層以濃鹽 酸酸化至ρΗ=ι後,以二氣甲烷萃取,萃取液經乾燥與濃縮 得到( + )伊托多雷(40 克,98〇/〇),[a]D = + 24_95/ (c=zl 〇,乙 醇),光學純度99,0%。 --------.1 ------订-------*4ri (請先閱讀背面之注意事項鼻填寫本頁) 經濟部中央標隼局員工消費合作社印裝 標 家 國 國 中 用 適 度 尺 張 紙 S Ν 格 規 4Printed by the Central Bureau of Standards of the Ministry of Economic Affairs—Industrial and Consumer Cooperatives / 12 6 6 8 5, A7 B7 V. Description of the invention (8) Derivatives (5.7 g, 87.66%). It is a white solid with a melting point of 48. -49 ° C > * H NMR (CDC13, 500 MHz), 5.11 (m, 1H), 4.99 (s, 1H), 3.65 (s, 3H), 2.79 (m, 2H), 2.60 (m, 1H) , 2.40 (m, 1H), 2.15 (m, 1H), 1.95 (m, 1H), 1.85 (m, 1H), 1.73 (m, 2H), 1.24 (s, 3H), 1.11 (m, 6H), 0.97 (s, 3H) 〇 If p-toluene.sulfonic acid (1 g) is used instead of DOWEX-50W for the same reaction, the excess trimethyl orthoformate is removed by vacuum distillation, and the concentrated solution is diluted with digas methane. After regeneration, the solution was washed with a 10% NaCO3 solution and then with water. The organic solution was dried over anhydrous magnesium sulfate, and concentrated to obtain a 3-ketovalerate allyl-ether derivative (5.16 g, 80%). Example 4 Cyclization of 7-ethylchromeol and .3-ketovalerate to prepare ester non-enantiomeric isomers 7-ethylchromeol (22.5 g, 0.119 moles) and The obtained 3-ketovalerate (30 g, 0.119 mole) was dissolved in dry digas methane (500 ml) and added; 8? 3 (^ 12 (10 ml, 0.0796 mole) ), And then stirred at room temperature for 12 hours. The resulting solution was diluted with ice water, and then washed with 10% sodium carbonate aqueous solution, and then washed with water. The organic solution was dried over anhydrous magnesium sulfate and concentrated. The residue was concentrated with benzene. Recrystallize with a mixed solvent of petroleum ether to obtain the desired diastereoisomer (31 g, 60%). The analysis data is the same as that of the compound prepared in Example 1. Column), the ratio of the di-isomers is about 1: 1. Example 5 Cyclization of 7-ethylchromeol and an ene ether derivative of 3-ketovalerate to make the paper scale applicable to the Chinese National Standard (CNS ) A4 size (210 X 297 mm) -------- 「—! ^ ------ Order ------ r「 f Please read the precautions on the back of Jing before filling this page 4 2668 5. Economy Printed on A7 B7 by the Consumers 'Cooperative of the Central Bureau of Quasi-Economy. 5. Description of the invention (9) Preparation of ester diastereomers: 7-ethyl tryptanol (29.2 g' 0.154 mol) and the one obtained in Example 3 3_ Ketovalerate's ether derivatives (4.1 g, 0,154 moles) were dissolved in dry digas methane (2500 ml) and a catalytic amount of BF3OEt2 (0.6 ml, 4.77 mmol) was added and then at room temperature After stirring for 2 hours, the resulting solution was diluted with ice water, and then washed with a 1Q% sodium bicarbonate aqueous solution, and then washed with water. The organic solution was concentrated after drying over anhydrous magnesium sulfate, and the residue was mixed with benzene and petroleum ether. The solvent was recrystallized to obtain the desired diastereomer (58 g '89%). The analytical data was the same as that of the compound prepared in Example 1' by HPLC analysis (palm tube. Column). The ratio of the isomers is about 1: 1. Example 6 Partial Crystallization of Ester Diastereomers The ester diastereomers (10 g, 0.0236 mole) was added to 70 ml of absolute ethanol, and after stirring for 15-15 minutes, the solution appeared clear Then, when the solution was cooled to room temperature, 50 mg of an ester compound formed by esterification of (+)-Itodol and (1R, 2R, 3R, 5SH-)-isosinol was added. As a seed crystal, the needle crystals (5.99 g, 60%) were collected by β filtration after standing at 0 ° C for 4 hours, and the melting point was 115-117 ° C, [a] D = -72. (C = l'0, ethanol). Example 7 (Ten Itorodore and (1R, 2R, 3R, 5SV1 Epinenol) Take the needle-shaped crystals that were early separated from Example 6, grams, Moore) and hydrogen Potassium oxide (3.5 g, 0.06 25 mol) was added to methanol (100 ml) and water (26 ml) and then heated under reflux for 2 hours, and the resulting solution was distilled off under reduced pressure. This paper is in accordance with Chinese national standards (CNS ) Λ4 gauge pile (210X ^ 7 male rear) " --------- V ------ Order -------, "(Please read the precautions on the back before filling in this Page} A7 V. Description of the invention (10) Methanol, after diluting the residual liquid with water, #extract with methane, the extract was recovered by drying and concentration (1R, 2R, 3R, 5S) _Isopyron algae (2 38g, 98 / 〇), all of its analysis data are with the commercial standard The same product. The aqueous layer was acidified with concentrated hydrochloric acid to ρΗ = ι, and then extracted with methane gas. The extract was dried and concentrated to obtain (+) Itodore (40 g, 98〇 / 〇). (c = zlO, ethanol), optical purity 99.0%. --------. 1 ------ Order ------- * 4ri (Please read the notes on the back first and fill out this page) Printed by the Staff Consumer Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs Standard home country and middle school use moderate rule paper S Ν grid 4

ΜΜ

Claims (1)

為月614(%知利、;s —中文申圍名 公(8緣9月 六、申請專利範囷 1· 一種抗關節炎用藥伊托多雷(etodolac)之光學解析方法 ,其包括: υ形成(土)-伊托多雷與(ir,2R,3R,5S)_㈠異松藻醇 (isopinocamphen〇l)之酯類非對映體異構物; 2) 於適當溶劑中進行部份結晶作用以分離所得之酯類 非對映體異構物,其中該適當溶劑係選自c5_c1()烷類 、Cl-Ce脂族醇、經1-3個鹵原子取代tCi_C6燒類和 缔類、C2_C〗0醚類、苯、甲苯、或二甲笨、或二或多 種此等溶劑之混合物;及 3) 進行水解作用以回收單一伊托多雷光學異構物。 2 ·根據申請專利範圍第1項之方法,其中步驟丨)形成酯類 非對映體異構物之方式包括a) (±)_伊托多雷與(1R, 2R, 3R,5S)-(-)_異松藻醇直接反應生成該酯類非對映體異 構物,或b)將7-乙基色醇與一種3-酮基戊酸酯或其烯醚 型衍生物於路易士酸存在下,經環化反應以形式該酯類 非斜映體異構物,其中3-酮基戊酸酯係由3_酮基戊酸與 (1R,2R,3R,5S)-異松藻醇之酯化反應所製得。 3.根據申請專利範圍第2項之方法,其中路易士酸係選自 齒化硼、自化磷、二氣化鋅、四氣化錫或齒化鋁。 4·根據申請專利範圍第1項之方法,其中部份結晶作用所 使用之溶劑為Ci-Ce脂族醇。 5_根據_請專利範圍第4項之方法,其中部份結晶所使用 之溶劑是無水乙醇。 6_根據申凊專利範圍第1項之方法,其中步驟2)之結晶作 娜尺度通^ -¾— (請先聞讀背面之注意事項再填寫本X ) II 經濟部中央標準局貝工消費合作社印製For the month 614 (% Zhili ,; s — Chinese applied for the name of the public (September 6th, application for a patent 囷 1 · An optical analysis method for the anti-arthritis drug etodolac), which includes: υ Form (earth) -esterol diastereomers of itodore and (ir, 2R, 3R, 5S) _isopinocamphenol; 2) Partial crystallization in a suitable solvent Function to separate the ester diastereomers obtained, wherein the appropriate solvent is selected from the group consisting of c5_c1 () alkanes, Cl-Ce aliphatic alcohols, tCi_C6 compounds substituted with 1-3 halogen atoms, and associations, C2_C: 0 ethers, benzene, toluene, or dimethylbenzyl, or a mixture of two or more of these solvents; and 3) performing hydrolysis to recover a single itodore optical isomer. 2 · The method according to item 1 of the scope of patent application, wherein the method of step 丨) forming ester diastereomers includes a) (±) _Itodole and (1R, 2R, 3R, 5S)- (-) _ Isospinol reacts directly to generate the ester diastereomer, or b) 7-ethylchromeol and a 3-ketovalerate or its ether derivative in Louis In the presence of an acid, this ester is a non-enantiomeric isomer through a cyclization reaction, in which 3-ketovalerate is composed of 3-ketovaleric acid and (1R, 2R, 3R, 5S) -iso pine It is prepared by esterification of alginate. 3. The method according to item 2 of the scope of patent application, wherein the Lewis acid is selected from the group consisting of dentified boron, autophosphorus, zinc digas, tin tetragas, or aluminum. 4. The method according to item 1 of the scope of patent application, wherein the solvent used for part of the crystallization is Ci-Ce aliphatic alcohol. 5_ According to the method in item 4 of the patent scope, the solvent used for some of the crystallization is anhydrous ethanol. 6_ The method according to item 1 of the scope of patent application, wherein the crystallization of step 2) is made by the standard ^ -¾— (please read the notes on the back before filling in this X) II Shellfish Consumption of the Central Standards Bureau of the Ministry of Economic Affairs Printed by a cooperative CHO 426685, 儲 C8 D8 々、申請專利範圍 用可藉晶種之添加而增加結晶速率。 7. 根據申請專利範圍第3項之方法,其中路易士酸係選自 BF3 OEt!或 BF3。 8, —種具有如下化學式結構之酯: (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局男工消費合作社印製CHO 426685, storage C8 D8 々, patent application scope It can increase the crystallization rate by adding seed crystals. 7. The method according to item 3 of the scope of patent application, wherein the Lewis acid is selected from BF3 OEt! Or BF3. 8, —An ester with the following chemical structure: (Please read the notes on the back before filling out this page) Printed by the Male Workers Consumer Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs 本紙張尺度適用中國國家梯準(CNS ) A4現格(210 X 297公釐)This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) 為月614(%知利、;s —中文申圍名 公(8緣9月 六、申請專利範囷 1· 一種抗關節炎用藥伊托多雷(etodolac)之光學解析方法 ,其包括: υ形成(土)-伊托多雷與(ir,2R,3R,5S)_㈠異松藻醇 (isopinocamphen〇l)之酯類非對映體異構物; 2) 於適當溶劑中進行部份結晶作用以分離所得之酯類 非對映體異構物,其中該適當溶劑係選自c5_c1()烷類 、Cl-Ce脂族醇、經1-3個鹵原子取代tCi_C6燒類和 缔類、C2_C〗0醚類、苯、甲苯、或二甲笨、或二或多 種此等溶劑之混合物;及 3) 進行水解作用以回收單一伊托多雷光學異構物。 2 ·根據申請專利範圍第1項之方法,其中步驟丨)形成酯類 非對映體異構物之方式包括a) (±)_伊托多雷與(1R, 2R, 3R,5S)-(-)_異松藻醇直接反應生成該酯類非對映體異 構物,或b)將7-乙基色醇與一種3-酮基戊酸酯或其烯醚 型衍生物於路易士酸存在下,經環化反應以形式該酯類 非斜映體異構物,其中3-酮基戊酸酯係由3_酮基戊酸與 (1R,2R,3R,5S)-異松藻醇之酯化反應所製得。 3.根據申請專利範圍第2項之方法,其中路易士酸係選自 齒化硼、自化磷、二氣化鋅、四氣化錫或齒化鋁。 4·根據申請專利範圍第1項之方法,其中部份結晶作用所 使用之溶劑為Ci-Ce脂族醇。 5_根據_請專利範圍第4項之方法,其中部份結晶所使用 之溶劑是無水乙醇。 6_根據申凊專利範圍第1項之方法,其中步驟2)之結晶作 娜尺度通^ -¾— (請先聞讀背面之注意事項再填寫本X ) II 經濟部中央標準局貝工消費合作社印製For the month 614 (% Zhili ,; s — Chinese applied for the name of the public (September 6th, application for a patent 囷 1 · An optical analysis method for the anti-arthritis drug etodolac), which includes: υ Form (earth) -esterol diastereomers of itodore and (ir, 2R, 3R, 5S) _isopinocamphenol; 2) Partial crystallization in a suitable solvent Function to separate the ester diastereomers obtained, wherein the appropriate solvent is selected from the group consisting of c5_c1 () alkanes, Cl-Ce aliphatic alcohols, tCi_C6 compounds substituted with 1-3 halogen atoms, and associations, C2_C: 0 ethers, benzene, toluene, or dimethylbenzyl, or a mixture of two or more of these solvents; and 3) performing hydrolysis to recover a single itodore optical isomer. 2 · The method according to item 1 of the scope of patent application, wherein the method of step 丨) forming ester diastereomers includes a) (±) _Itodole and (1R, 2R, 3R, 5S)- (-) _ Isospinol reacts directly to generate the ester diastereomer, or b) 7-ethylchromeol and a 3-ketovalerate or its ether derivative in Louis In the presence of an acid, this ester is a non-enantiomeric isomer through a cyclization reaction, in which 3-ketovalerate is composed of 3-ketovaleric acid and (1R, 2R, 3R, 5S) -iso pine It is prepared by esterification of alginate. 3. The method according to item 2 of the scope of patent application, wherein the Lewis acid is selected from the group consisting of dentified boron, autophosphorus, zinc digas, tin tetragas, or aluminum. 4. The method according to item 1 of the scope of patent application, wherein the solvent used for part of the crystallization is Ci-Ce aliphatic alcohol. 5_ According to the method in item 4 of the patent scope, the solvent used for some of the crystallization is anhydrous ethanol. 6_ The method according to item 1 of the scope of patent application, wherein the crystallization of step 2) is made by the standard ^ -¾— (please read the notes on the back before filling in this X) II Shellfish Consumption of the Central Standards Bureau of the Ministry of Economic Affairs Printed by a cooperative
TW86110781A 1997-07-29 1997-07-29 Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac TW426685B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW86110781A TW426685B (en) 1997-07-29 1997-07-29 Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW86110781A TW426685B (en) 1997-07-29 1997-07-29 Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac

Publications (1)

Publication Number Publication Date
TW426685B true TW426685B (en) 2001-03-21

Family

ID=21626856

Family Applications (1)

Application Number Title Priority Date Filing Date
TW86110781A TW426685B (en) 1997-07-29 1997-07-29 Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac

Country Status (1)

Country Link
TW (1) TW426685B (en)

Similar Documents

Publication Publication Date Title
US11325875B2 (en) Compound having chiral spirobiindane skeleton and preparation method therefor
Loupy et al. Isomannide and isosorbide as new chiral auxiliaries for the stereoselective synthesis of tertiary α-hydroxy acids
Utermoehlen et al. Fjord region 3, 4-diol 1, 2-epoxides and other derivatives in the 1, 2, 3, 4-and 5, 6, 7, 8-benzo rings of the carcinogen benzo [g] chrysene
US9771317B2 (en) Process for preparing lacosamide and related compounds
EP1889827A1 (en) Intermediate in production of [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound
JP4997106B2 (en) Production intermediate of [2- (3,3,5,5-tetramethylcyclohexyl) phenyl] piperazine compound
TW426685B (en) Diastereomeric esters of etodolac-an antiarthritic drug and method for the optical resolution of etodolac
WO2011086570A1 (en) Process for preparation of cyanoalkylpropionate derivatives
CN110041309A (en) A kind of Tacrine -8- amino (hydroxyl) quinoline of 2- carboxypiperazin connection and preparation and application
KR20120091971A (en) Preparation method for entecavir
WO2011141928A1 (en) Process for the preparation of highly pure bexarotene
Ogura et al. New synthetic route to an. alpha.-alkoxy-. alpha.-arylacetic ester using formaldehyde dimethyl dithioacetal S, S-dioxide
CN111777554A (en) Method for synthesizing cisatracurium besilate
Newkome et al. Chiral cyclic olefins. 1. Synthesis, resolution, and stereochemistry of 5-hydroxy-10-alkyl-. DELTA. 1 (9)-2-octalones
JPS638954B2 (en)
TW201531478A (en) Process for production of quinuclidine compounds
RU2005717C1 (en) Process for preparing aralkylamine derivatives or their acid addition salts
JP3911302B2 (en) Process for producing optically active 2-methylpiperazine
JP2605538B2 (en) Chiral derivatization reagent and separation analysis method using the same
JP3084577B2 (en) Method for producing optically active atrolactic acid and intermediate for production
JP3009860B2 (en) Method for producing (±) 2- [4- (2-oxocyclopentylmethyl) phenyl] propionic acid and salts thereof
JP2977591B2 (en) Method for producing benzene derivative
JPS5927333B2 (en) Process for producing clemastine fumarate useful as a medicine
Michne et al. Benzo [g] quinolines. II. Novel synthesis and pharmacological evaluation of cis-1-alkyl-1, 2, 3, 4, 4a, 5, 10, 10a-octahydrobenzo [g] quinolines
JPH0791264B2 (en) N- (2-amino-3-hydroxybenzoyl) -L-prolinal acetal and process for producing the same

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees